HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bloomgarden, Z. T. Search for Related Content PubMed PubMed Citation Articles by Bloomgarden, Z. T. Social Bookmarking                What's this?

2nd International Symposium on Triglycerides and HDL

Metabolic syndrome

Zachary T. Bloomgarden, MD, is a practicing endocrinologist in New York, New York, and is affiliated with the Division of Endocrinology, Mount Sinai School of Medicine, New York, New York

Abbreviations: apo, apolipoprotein • ATP III, Adult Treatment Panel III • CHD, coronary heart disease • CRP, C-reactive protein • CVD, cardiovascular disease • DPP, Diabetes Prevention Program • IDF, International Diabetes Federation • IB, inhibitor of NF-B • IL, interleukin • LPL, lipoprotein lipase • NF, nuclear factor • PPAR, peroxisome proliferator–activated receptor • RIO, Rimonabant in Overweight/Obesity • TNF, tumor necrosis factor • VA-HIT, Veterans Affairs High-Density Lipoprotein Intervention Trial • WHO, World Health Organization

The first 300 words of the full text of this article appear below.

This is the first of two articles summarizing the 2nd International Symposium on Triglycerides and HDL, organized by the Giovanni Lorenzini Medical Foundation and held in New York, New York, 14–17 July 2005.

Anthony Gotto (New York, NY) gave an overview of the "evolving story" of HDL and triglycerides in cardiovascular disease (CVD) prevention. He noted that statins only reduce clinical events by approximately one-third (although subsequent speakers suggested that with more aggressive LDL targets events may be reduced by half), and recommended targeting HDL and triglyceride in addition to LDL cholesterol to achieve greater degrees of risk reduction. There is as yet, however, no direct evidence of clinical benefit with this approach. In the early 1950s, the higher level of HDL cholesterol in women and the association of low HDL with CVD was first described, with the Framingham Heart Study recognizing low HDL as the "major potent lipid risk factor" in 1977 (1), and with recognition that each 1-mg/dl decrease in HDL is associated with a 2–3% increase in CVD risk later proposed by this group. Triglyceride also has been shown to be associated with CVD, although this is more controversial. In a meta-analysis of 17 population-based prospective studies of 46,413 men and 10,864 women, adjusting for HDL cholesterol and other risk factors, there were increases of 16 and 42% in CVD end points in men and in women, respectively, for every 100-mg/dl increase in triglyceride level (2). The National Cholesterol Education Program Adult Treatment Panel III (ATP III) recommended use of non-HDL cholesterol as a target of therapy if the triglyceride level exceeded 200 mg/dl. Triglycerides were recommended as a "secondary target" if levels exceeded 200 mg/dl, with nicotinic acid and fibrates useful pharmacologic approaches, and specific HDL cholesterol targets were not recommended (. . . [Full Text of this Article]

The metabolic syndrome

Obesity-related aspects of metabolic syndrome

Further treatment approaches for metabolic syndrome

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. I. Kakafika, D. P. Mikhailidis, A. Karagiannis, and V. G. Athyros The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome J. Clin. Pharmacol., May 1, 2007; 47(5): 642 - 652. [Abstract] [Full Text] [PDF]

				C. Popa, M. G. Netea, P. L. C. M. van Riel, J. W. M. van der Meer, and A. F. H. Stalenhoef The role of TNF-{alpha} in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk J. Lipid Res., April 1, 2007; 48(4): 751 - 762. [Abstract] [Full Text] [PDF]